Endocrine Abstracts

Mineralocorticoid receptor antagonists (MRAs) improve survival and reduce morbidity in patients with heart failure (HF), reduced ejection fraction (REF) with severe symptoms (RALES, spironolactone) or with mild symptoms (EMPHASIS-HF, eplerenone), and in patients with left ventricular systolic dysfunction and heart failure after acute myocardial infarction (MI) (EPHESUS, eplerenone). These clinical benefits are observed in addition to those of angiotensin-converting enzyme (ACE...